|Day Low/High||68.10 / 68.82|
|52 Wk Low/High||65.06 / 100.23|
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
Stocks see a nice surge on the open on optimism around trade talks resuming between the U.S. and China, although negotiations will be ongoing for many months and no permanent resolution seems on the horizon. The U.S. PMI Manufacturing Index also cam...
It is good to be sitting in for Doug Kass here on The Daily Diary as we open trading in the second half of 2019. June ended on an up note as all the major indices drifted up last week to close out the month and quarter. The market did an admirable j...
Watch the Russell 2000, housing activity, and mergers and acquisitions.
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
With no other bidder expected to emerge, this is a high risk arbitrage play.
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
Let's look closer at the charts and indicators of ABBV.
AbbVie is dropping on Allergan deal announcement, momentum is weak outside certain pockets.
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
As we have seen so far, in terms of market reaction, there is great reward at the point of sale in beating expectations.
Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.
Experts offer their top stock ideas in oncology detection and treatment.
China's central bank announced a bill swap mechanism late Thursday aimed at slowing down the nation's economic slowdown.
One of pharma's biggest CEO's talks M&A action on the exchange.
And it is happening not a moment too soon.
Dow Theory presents tips for surviving a bear market, some top year-end stock bargains and a simple strategy for monthly income.
SHAK beat expectations for both EPS and revenue, but same-store sales decreased. Here is how I would play it.
Once the safest stocks in the book, the big-cap drug companies are now toxic.
There are no catalysts to drive the stock price higher, so for now, Gilead is simply a cheap stock with a nice dividend.
This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.
This stock is still going wild after earnings.